ActiQs / Forskning

PUBLIKATIONSREGISTRET

Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för PF-06409577. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

13 träffar

Bibliografisk träff 2023-10-20

Macrophage AMPK β1 activation by PF-06409577 reduces the inflammatory response, cholesterol synthesis, and atherosclerosis in mice.

Day EA, Townsend LK, Rehal S, Batchuluun B, Wang D, Morrow MR, Lu R, Lundenberg L, Lu JH, Desjardins EM, Smith TKT, Raphenya AR, McArthur AG, Fullerton MD, Steinberg GR.

iScience · research-article; journal article · DOI 10.1016/j.isci.2023.108269

Bibliografisk träff 2023-04-06

AMP-activated protein kinase activators have compound and concentration-specific effects on brain metabolism.

Achanta LB, Thomas DS, Housley GD, Rae CD.

J Neurochem · research support, non-u.s. gov't; journal article · DOI 10.1111/jnc.15815

Bibliografisk träff 2022-07-04

PF-06409577 inhibits renal cyst progression by concurrently inhibiting the mTOR pathway and CFTR channel activity.

Su L, Yuan H, Zhang H, Wang R, Fu K, Yin L, Ren Y, Liu H, Fang Q, Wang J, Guo D.

FEBS Open Bio · research support, non-u.s. gov't; research-article; journal article · DOI 10.1002/2211-5463.13459

Bibliografisk träff 2022-03-16

Opposing effects on regulated insulin secretion of acute vs chronic stimulation of AMP-activated protein kinase.

Nguyen-Tu MS, Harris J, Martinez-Sanchez A, Chabosseau P, Hu M, Georgiadou E, Pollard A, Otero P, Lopez-Noriega L, Leclerc I, Sakamoto K, Schmoll D, Smith DM, Carling D, Rutter GA.

Diabetologia · research support, non-u.s. gov't; research-article; journal article · DOI 10.1007/s00125-022-05673-x

Bibliografisk träff 2021-07-14

PF-06409577 Activates AMPK Signaling and Inhibits Osteosarcoma Cell Growth.

Zhu YR, Zhang XY, Wu QP, Yu CJ, Liu YY, Zhang YQ.

Front Oncol · research-article; journal article · DOI 10.3389/fonc.2021.659181

Bibliografisk träff 2020-05-15

The AMP-activated protein kinase modulates hypothermia-induced J wave.

Wu CI, Lu YY, Chen YC, Lin FZ, Huang JH, Lin YK, Higa S, Chan CS, Liu CM, Chen SA, Chen YJ.

Eur J Clin Invest · journal article · DOI 10.1111/eci.13247

Bibliografisk träff 2018-09-07

6-Chloro-5-[4-(1-Hydroxycyclobutyl)Phenyl]-1H-Indole-3-Carboxylic Acid is a Highly Selective Substrate for Glucuronidation by UGT1A1, Relative to β-Estradiol.

Lapham K, Lin J, Novak J, Orozco C, Niosi M, Di L, Goosen TC, Ryu S, Riccardi K, Eng H, Cameron KO, Kalgutkar AS.

Drug Metab Dispos · journal article · DOI 10.1124/dmd.118.083709

Bibliografisk träff 2018-08-02

Acyl Glucuronide Metabolites of 6-Chloro-5-[4-(1-hydroxycyclobutyl)phenyl]-1 H-indole-3-carboxylic Acid (PF-06409577) and Related Indole-3-carboxylic Acid Derivatives are Direct Activators of Adenosine Monophosphate-Activated Protein Kinase (AMPK).

Ryder TF, Calabrese MF, Walker GS, Cameron KO, Reyes AR, Borzilleri KA, Delmore J, Miller R, Kurumbail RG, Ward J, Kung DW, Brown JA, Edmonds DJ, Eng H, Wolford AC, Kalgutkar AS.

J Med Chem · research support, u.s. gov't, non-p.h.s.; journal article · DOI 10.1021/acs.jmedchem.8b00807

Bibliografisk träff 2018-06-26

Direct Activation of Adenosine Monophosphate-Activated Protein Kinase (AMPK) by PF-06409577 Inhibits Flavivirus Infection through Modification of Host Cell Lipid Metabolism.

Jiménez de Oya N, Blázquez AB, Casas J, Saiz JC, Martín-Acebes MA.

Antimicrob Agents Chemother · research support, non-u.s. gov't; research-article; journal article · DOI 10.1128/aac.00360-18

Bibliografisk träff 2018-05-08

PF-06409577 activates AMPK signaling to protect retinal pigment epithelium cells from UV radiation.

Li XF, Liu XM, Huang DR, Cao HJ, Wang JY.

Biochem Biophys Res Commun · research support, non-u.s. gov't; journal article · DOI 10.1016/j.bbrc.2018.05.003

Bibliografisk träff 2018-04-08

Activation of Liver AMPK with PF-06409577 Corrects NAFLD and Lowers Cholesterol in Rodent and Primate Preclinical Models.

Esquejo RM, Salatto CT, Delmore J, Albuquerque B, Reyes A, Shi Y, Moccia R, Cokorinos E, Peloquin M, Monetti M, Barricklow J, Bollinger E, Smith BK, Day EA, Nguyen C, Geoghegan KF, Kreeger JM, Opsahl A, Ward J, Kalgutkar AS, Tess D, Butler L, Shirai N, Osborne TF, Steinberg GR, Birnbaum MJ, Cameron KO, Miller RA.

EBioMedicine · research-article; journal article · DOI 10.1016/j.ebiom.2018.04.009

Bibliografisk träff 2017-03-13

Selective Activation of AMPK β1-Containing Isoforms Improves Kidney Function in a Rat Model of Diabetic Nephropathy.

Salatto CT, Miller RA, Cameron KO, Cokorinos E, Reyes A, Ward J, Calabrese MF, Kurumbail RG, Rajamohan F, Kalgutkar AS, Tess DA, Shavnya A, Genung NE, Edmonds DJ, Jatkar A, Maciejewski BS, Amaro M, Gandhok H, Monetti M, Cialdea K, Bollinger E, Kreeger JM, Coskran TM, Opsahl AC, Boucher GG, Birnbaum MJ, DaSilva-Jardine P, Rolph T.

J Pharmacol Exp Ther · journal article · DOI 10.1124/jpet.116.237925

Bibliografisk träff 2016-08-20

Discovery and Preclinical Characterization of 6-Chloro-5-[4-(1-hydroxycyclobutyl)phenyl]-1H-indole-3-carboxylic Acid (PF-06409577), a Direct Activator of Adenosine Monophosphate-activated Protein Kinase (AMPK), for the Potential Treatment of Diabetic Nephropathy.

Cameron KO, Kung DW, Kalgutkar AS, Kurumbail RG, Miller R, Salatto CT, Ward J, Withka JM, Bhattacharya SK, Boehm M, Borzilleri KA, Brown JA, Calabrese M, Caspers NL, Cokorinos E, Conn EL, Dowling MS, Edmonds DJ, Eng H, Fernando DP, Frisbie R, Hepworth D, Landro J, Mao Y, Rajamohan F, Reyes AR, Rose CR, Ryder T, Shavnya A, Smith AC, Tu M, Wolford AC, Xiao J.

J Med Chem · research support, non-u.s. gov't; research support, u.s. gov't, non-p.h.s.; journal article · DOI 10.1021/acs.jmedchem.6b00866

Gå till forskningen.

Publikationer i urvalet

Macrophage AMPK β1 activation by PF-06409577 reduces the inflammatory response, cholesterol synthesis, and atherosclerosis in mice.

AMP-activated protein kinase activators have compound and concentration-specific effects on brain metabolism.

PF-06409577 inhibits renal cyst progression by concurrently inhibiting the mTOR pathway and CFTR channel activity.

Opposing effects on regulated insulin secretion of acute vs chronic stimulation of AMP-activated protein kinase.

PF-06409577 Activates AMPK Signaling and Inhibits Osteosarcoma Cell Growth.

The AMP-activated protein kinase modulates hypothermia-induced J wave.

6-Chloro-5-[4-(1-Hydroxycyclobutyl)Phenyl]-1<i>H</i>-Indole-3-Carboxylic Acid is a Highly Selective Substrate for Glucuronidation by UGT1A1, Relative to <i>β</i>-Estradiol.

Acyl Glucuronide Metabolites of 6-Chloro-5-[4-(1-hydroxycyclobutyl)phenyl]-1 H-indole-3-carboxylic Acid (PF-06409577) and Related Indole-3-carboxylic Acid Derivatives are Direct Activators of Adenosine Monophosphate-Activated Protein Kinase (AMPK).

Direct Activation of Adenosine Monophosphate-Activated Protein Kinase (AMPK) by PF-06409577 Inhibits Flavivirus Infection through Modification of Host Cell Lipid Metabolism.

PF-06409577 activates AMPK signaling to protect retinal pigment epithelium cells from UV radiation.

Activation of Liver AMPK with PF-06409577 Corrects NAFLD and Lowers Cholesterol in Rodent and Primate Preclinical Models.

Selective Activation of AMPK <i>β</i>1-Containing Isoforms Improves Kidney Function in a Rat Model of Diabetic Nephropathy.

Discovery and Preclinical Characterization of 6-Chloro-5-[4-(1-hydroxycyclobutyl)phenyl]-1H-indole-3-carboxylic Acid (PF-06409577), a Direct Activator of Adenosine Monophosphate-activated Protein Kinase (AMPK), for the Potential Treatment of Diabetic Nephropathy.